Vyteris completes Phase I peptide dose ranging study

In the Phase I dose ranging study, four different electronic profiles were used to control the transdermal delivery of the peptide from patches loaded with different concentrations of the peptide.

By varying the electronic profile from the Smart Patch, the amount of peptide delivered was adjusted above and below the typical therapeutic levels based on subcutaneous and intravenous injections.

The product under development by would employ Vyteris’s patented Smart Patch drug delivery technology. The patch is designed to provide a safe and effective method of delivering drugs via a pre-programmed regulating system, a characteristic important in the delivery of therapeutics for the treatment of female infertility.

The patch is also designed to administer the peptide without needles and is being designed to deliver multiple transdermal pulses automatically, around the clock in a painless, convenient and cost-effective manner.

According to the company, the dose ranging study represents an important step in the clinical development of a product for female fertility treatment. The results from this study will be used to establish the multiple dose levels of the proposed peptide for a Phase II study.